Significant pharmacogenomic diversity exists between Southeast Asian and European populations, which correlates with population-specific risks for adverse drug reactions such as those to clopidogrel.
Answers are grounded in this paper and cite their sources.
May warrant ancestry-informed clopidogrel caution in Southeast Asians; extends CYP2C19 risk data beyond European cohorts.
Differences in the frequency of pharmacogenomic variants may influence inter-population variability in drug efficacy and risk of adverse drug reactions (ADRs). We investigated the diversity of ∼ 4500 genetic variants in key drug-biotransformation and -response genes among three South East Asian populations compared with individuals of European ancestry. We compared rates of reported ADRs in these Asian populations to determine if the allelic differentiation corresponded to an excess of the associated ADR. We identified an excess of ADRs related to clopidogrel in Singaporean Chinese, consistent with a higher frequency of a known risk variant in CYP2C19 in that population. We also observed an excess of ADRs related to platinum compounds in Singaporean CHS, despite a very low frequency of known ADR risk variants, suggesting the presence of additional genetic and non-genetic risk factors. Our results point to substantial diversity at specific pharmacogenomic loci that may contribute to inter-population variability in drug response phenotypes.
No takes yet. Share an insight, caveat, or question.
Brunham et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: